Basic Information
| LncRNA/CircRNA Name | HAGLROS |
| Synonyms | NA |
| Region | GRCh38_2:176177717-176179008 |
| Ensemble | ENSG00000226363 |
| Refseq | NR_110457 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR |
| Sample | ovarian cancer samples and 40 normal ovarian tissue |
| Expression Pattern | up-regulated |
| Function Description | HAGLROS was signifcantly upregulated in ovarian cancer (P<0.001) and was closely related to disease stage (P=0.033), tumour size (P=0.032) and poor prognosis (P=0.019). HAGLROS had a certain diagnostic value in ovarian cancer (area under the curve=0.751). MiR-100 was negatively correlated with HAGLROS (r=0.167, P=0.001) and signifcantly downregulated in ovarian cancer. Bioinformatics analysis predicted a total of 31 potential target genes that interact with miR-100. These target genes were mainly involved in the regulation of cellular catabolic process, proteoglycan biosynthetic process and positive regulation of proteasomal ubiquitin-dependent protein catabolic process. Among them, mTOR and ZNRF2 are hub genes. |
| Pubmed ID | 31197441 |
| Year | 2019 |
| Title | Clinical signifcance and oncogene function of long noncoding RNA HAGLROS overexpression in ovarian cancer |
External Links
| Links for HAGLROS | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |